The San Diego-based company’s Celution system automates the extraction and concentration of autologous, clinical-grade adipose-derived regenerative cells. The next-gen Celution tech includes new hardware and software to improve performance and maintain compliance with global medical device and cell therapy standards, Cytori said.
“Cytori continues to evolve its technology platforms as it simultaneously advances its clinical programs,” John Harris, VP and GM of cell therapy, said in prepared remarks. “This new technology, partially supported through our BARDA contract, will be the cornerstone of our U.S. Relief clinical trial for thermal burn injuries and potential U.S. FDA PMA submission for Habeo Cell Therapy for scleroderma-associated hand dysfunction.”
“This announcement marks the most significant new evolution of our cell therapy technology in years,” VP of global marketing Russ Havranek added. “This enhanced product offering should immediately resonate with our current installed base in a variety of countries and potential new customers interested in clinical cell therapy for reconstructive, aesthetic and orthopedic conditions.”
Cytori’s cell therapy is derived from human adipose tissue, or fat, and is also known as adipose-derived regenerative cells. Because the regenerative cells come from the patient’s body, treatment with these cells avoid cell rejection and do not require immunosuppressive drugs.
Previous studies have shown that the cells can promote angiogenesis – the creation of new blood vessels from pre-existing vessels. Preclinical studies also demonstrated that the regenerative cells are associated with wound healing, promoting the expression of extracellular matrix components and remodeling enzymes.
CYTX shares were trading at $1.04 in mid-morning activity today, up 4%.